Pipeline
From Discovery to Phase II
BT-924 is currently in preclinical development — a first-in-class non-systemic therapy designed to redefine metabolic treatment in obesity.
Program
Discovery
IND-enabling
Phase I
Phase II
BT-924
Program
Discovery
IND-enabling
Phase I
Phase II
EL-615
Program
Discovery
IND-enabling
Phase I
Phase II
EL-787
BT-924
Redefining metabolic treatment in obesity.
BT-924 is a first-in-class therapeutic designed to address obesity through modulation of the body’s intrinsic metabolic regulation — moving beyond traditional approaches centered on calorie restriction or appetite suppression.
Potentially addressing key limitations of current standard-of-care therapies.
Differentiation
Designed to overcome the limitations of today's therapies.
Today's standard of care
Limitations of GLP-1 / GIP therapies
Lean mass loss associated with weight reduction
Gastrointestinal tolerability limitations in a substantial subset of patients
High pill or injection burden impacting long-term adherence
BT-924
Designed to overcome prior limitations
Lower dose profile
Robust observed biological effect
Early human data suggesting favorable tolerability
Early signals suggesting preservation of lean mass during weight loss
Profile
A non-systemic, mechanistically distinct therapy.
Differentiated safety profile
Local activity in the proximal small intestine with minimal systemic exposure.
Combinable with existing therapies
Mechanism complements — and is distinct from — current standard of care.
Broad applicability
Designed for obesity, insulin resistance, and related metabolic conditions.